Literature DB >> 32985676

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma.

Hanna Eriksson1, Johan Hansson, Britta Krynitz, Giuseppe Masucci, Ada Girnita, Jan Lapins, Auris O Huen, Hussein A Tawbi, Michael A Davies, Michael T Tetzlaff, Jonathan L Curry.   

Abstract

Entities:  

Keywords:  bullous pemphigoid; targeted therapy; melanoma

Mesh：

Year:  2020        PMID： 32985676      PMCID： PMC9309853          DOI： 10.2340/00015555-3648

Source DB:  PubMed          Journal:  Acta Derm Venereol        ISSN： 0001-5555            Impact factor:   3.875


× No keyword cloud information.
  14 in total

1.  Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230.

Authors:  Sybille Thoma-Uszynski; Wolfgang Uter; Susanne Schwietzke; Gerold Schuler; Luca Borradori; Michael Hertl
Journal:  J Immunol       Date:  2006-02-01       Impact factor: 5.422

2.  Histological features associated with vemurafenib-induced skin toxicities: examination of 141 cutaneous lesions biopsied during therapy.

Authors:  Jonathan L Curry; Michael T Tetzlaff; Kimberly Nicholson; Madeleine Duvic; Kevin B Kim; Kenneth Y Tsai; Wen-Jen Hwu; David S Hong; Victor G Prieto; Carlos A Torres-Cabala
Journal:  Am J Dermatopathol       Date:  2014-07       Impact factor: 1.533

Review 3.  Diagnosis and classification of autoimmune blistering diseases.

Authors:  Sharon Baum; Nicole Sakka; Ofir Artsi; Henri Trau; Aviv Barzilai
Journal:  Autoimmun Rev       Date:  2014-01-13       Impact factor: 9.754

Review 4.  Diverse types of dermatologic toxicities from immune checkpoint blockade therapy.

Authors:  Jonathan L Curry; Michael T Tetzlaff; Priyadharsini Nagarajan; Carol Drucker; Adi Diab; Sharon R Hymes; Madeleine Duvic; Wen-Jen Hwu; Jennifer A Wargo; Carlos A Torres-Cabala; Ronald P Rapini; Victor G Prieto
Journal:  J Cutan Pathol       Date:  2016-12-21       Impact factor: 1.587

5.  Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions.

Authors:  George Jour; Isabella C Glitza; Rachel M Ellis; Carlos A Torres-Cabala; Michael T Tetzlaff; Janet Y Li; Priyadharsini Nagarajan; Auris Huen; Phyu P Aung; Doina Ivan; Carol R Drucker; Victor G Prieto; Ronald P Rapini; Anisha Patel; Jonathan L Curry
Journal:  J Cutan Pathol       Date:  2016-05-08       Impact factor: 1.587

Review 6.  Pemphigoid diseases.

Authors:  Enno Schmidt; Detlef Zillikens
Journal:  Lancet       Date:  2012-12-11       Impact factor: 79.321

Review 7.  Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.

Authors:  Adil Daud; Katy Tsai
Journal:  Oncologist       Date:  2017-05-18

8.  Selective BRAF inhibitors induce marked T-cell infiltration into human metastatic melanoma.

Authors:  James S Wilmott; Georgina V Long; Julie R Howle; Lauren E Haydu; Raghwa N Sharma; John F Thompson; Richard F Kefford; Peter Hersey; Richard A Scolyer
Journal:  Clin Cancer Res       Date:  2011-12-12       Impact factor: 12.531

9.  A predominant IgG4 subclass may be responsible for false-negative direct immunofluorescence in bullous pemphigoid.

Authors:  Kerry E Buschman; Mark Seraly; H Y Thong; Jau-Shyong Deng; Rose P Draviam; John L Abernethy
Journal:  J Cutan Pathol       Date:  2002-05       Impact factor: 1.587

10.  A Systematic Review of Drug-Induced Pemphigoid.

Authors:  Matthew J Verheyden; Asli Bilgic; Dédée F Murrell
Journal:  Acta Derm Venereol       Date:  2020-08-17       Impact factor: 3.875
View more
  1 in total

1.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.